Mazumder A - Search Results

1

Personalization of cancer treatment using predictive simulation.

Doudican NA, Kumar A, Singh NK, Nair PR, Lala DA, Basu K, Talawdekar AA, Sultana Z, Tiwari KK, Tyagi A, Abbasi T, Vali S, Vij R, Fiala M, King J, Perle M, Mazumder A. Doudican NA, et al. Among authors: mazumder a. J Transl Med. 2015 Feb 1;13:43. doi: 10.1186/s12967-015-0399-y. J Transl Med. 2015. PMID: 25638213 Free PMC article.

2

Predictive simulation approach for designing cancer therapeutic regimens with novel biological mechanisms.

Doudican NA, Mazumder A, Kapoor S, Sultana Z, Kumar A, Talawdekar A, Basu K, Agrawal A, Aggarwal A, Shetty K, Singh NK, Kumar C, Tyagi A, Singh NK, Darlybai JC, Abbasi T, Vali S. Doudican NA, et al. Among authors: mazumder a. J Cancer. 2014 Apr 25;5(6):406-16. doi: 10.7150/jca.7680. eCollection 2014. J Cancer. 2014. PMID: 24847381 Free PMC article.

3

Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.

Doudican NA, Wen SY, Mazumder A, Orlow SJ. Doudican NA, et al. Among authors: mazumder a. Oncol Rep. 2012 Nov;28(5):1851-8. doi: 10.3892/or.2012.1977. Epub 2012 Aug 22. Oncol Rep. 2012. PMID: 22922937 Free PMC article.

4

Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma.

Narayanan BA, Doudican NA, Park J, Xu D, Narayanan NK, Dasgupta R, Mazumder A. Narayanan BA, et al. Among authors: mazumder a. Anticancer Res. 2012 Nov;32(11):4697-707. Anticancer Res. 2012. PMID: 23155232 Free PMC article.

5

Identification of agents that promote endoplasmic reticulum stress using an assay that monitors luciferase secretion.

Doudican NA, Wen SY, Mazumder A, Orlow SJ. Doudican NA, et al. Among authors: mazumder a. J Biomol Screen. 2014 Apr;19(4):575-84. doi: 10.1177/1087057113517549. Epub 2013 Dec 26. J Biomol Screen. 2014. PMID: 24371212 Free PMC article.

6

Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.

Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, Martin T, Weng L, Park J, Fiala M, Faham M, Wolf J. Vij R, et al. Among authors: mazumder a. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):131-139.e1. doi: 10.1016/j.clml.2013.09.013. Epub 2013 Oct 2. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24629890

7

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Lonial S, et al. Among authors: mazumder a. J Clin Oncol. 2012 Jun 1;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547589 Clinical Trial.

8

Carfilzomib for the treatment of multiple myeloma.

Lue J, Goel S, Mazumder A. Lue J, et al. Among authors: mazumder a. Drugs Today (Barc). 2013 Mar;49(3):171-9. doi: 10.1358/dot.2013.49.3.1939264. Drugs Today (Barc). 2013. PMID: 23527321

9

Characterization of multiple myeloma clonal cell expansion and stromal Wnt/β-catenin signaling in hyaluronic acid-based 3D hydrogel.

Narayanan NK, Duan B, Butcher JT, Mazumder A, Narayanan BA. Narayanan NK, et al. Among authors: mazumder a. In Vivo. 2014 Jan-Feb;28(1):67-73. In Vivo. 2014. PMID: 24425838

10

Adenosine A2A receptor activation prevents wear particle-induced osteolysis.

Mediero A, Frenkel SR, Wilder T, He W, Mazumder A, Cronstein BN. Mediero A, et al. Among authors: mazumder a. Sci Transl Med. 2012 May 23;4(135):135ra65. doi: 10.1126/scitranslmed.3003393. Sci Transl Med. 2012. PMID: 22623741 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

572 results

Search Page